Fig. 2

ILC2 frequency increases in patients with high PSA values and impacts patients’ survival. A Correlation of ILC1 and ILC2 frequencies in patients with PCa (n = 48). B, C Ratios of ILC2/ILC1 (B) and ILCP/ILC1 (C) in HDs and patients with LG and HG PCa . D Correlations between circulating ILC2 frequency and PSA value (n = 48). (E) Frequency of ILC2s based on PSA levels of HDs (< 4 (n = 25)) and patients with PCa (< 4 (n = 5), 4–10 (n = 28) and > 10 ng/ml (n = 15) according to the National Comprehensive Cancer Network guidelines. (F) Survival analysis (likelihood ratio test) of patients with PCa (TCGA), stratified according to their risk score for an ILC2 gene signature. Survival of patients was higher in low-risk score patients (blue line) compared with high-risk patients (red line). Data shown as mean ± SEM (*p < 0.05 **p < 0.01; ****p < 0.0001) and analyzed by Wilcoxon and/or one-way ANOVA tests